APC
BCRX icon

Aspire Private Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Aspire Private Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$618 – 683
2024
Q2 		$618 Buy
+100
New +$552 ﹤0.01% 620

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Aspire Private Capital's BCRX Position: Q3 2024 in Review

Aspire Private Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2024, closing a stake of 100 shares — an estimated $618 sold.

Aspire Private Capital first reported a position in BCRX in Q2 2024 and held it in 1 quarter. The position peaked at $618 in Q2 2024. 257 funds tracked by Wall St. Rank hold BCRX as of Q3 2024.

  • Aspire Private Capital reported no remaining BioCryst Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Aspire Private Capital sold 100 BioCryst Pharmaceuticals shares in Q3 2024, an estimated $618.
  • Aspire Private Capital first reported a position in BioCryst Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Aspire Private Capital's BioCryst Pharmaceuticals position peaked at $618 in Q2 2024.
  • 257 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2024.

Based on Aspire Private Capital's 13F filing for Q3 2024, filed 25 Oct 2024.